{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Girls%2C+alone&page=65",
    "query": {
      "intervention": "Girls, alone",
      "page": 65
    },
    "page_size": 10
  },
  "pagination": {
    "page": 65,
    "page_size": 10,
    "total_count": 1546,
    "total_pages": 155,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Girls%2C+alone&page=66&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Girls%2C+alone&page=64&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T12:22:00.582Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03890341",
      "title": "Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Drospirenone/Ethinylestradiol",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64530440",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-01",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-26",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03890341"
    },
    {
      "nct_id": "NCT01150539",
      "title": "Effects of Exercise for Overweight Women With Polycystic Ovary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "16-week exercise training program",
          "type": "OTHER"
        },
        {
          "name": "Control Group without PCOS",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Pennington Biomedical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 30 Years · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2007-01",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2021-08-25",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01150539"
    },
    {
      "nct_id": "NCT01438359",
      "title": "A Drug-Drug Interaction Study of Furosemide and PA21",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PA21 and Furosemide with food",
          "type": "DRUG"
        },
        {
          "name": "No PA21; Furosemide with food",
          "type": "DRUG"
        },
        {
          "name": "PA21 with food and Furosemide 2hrs later",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2011-07",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-09-30",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438359"
    },
    {
      "nct_id": "NCT00041080",
      "title": "Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "tamoxifen citrate",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 139,
      "start_date": "2003-02",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041080"
    },
    {
      "nct_id": "NCT03578627",
      "title": "Stress and Immunity Breast Cancer Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer Stage II",
        "Breast Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "BioBehavioral Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 231,
      "start_date": "1994-05-01",
      "completion_date": "2000-05-31",
      "has_results": false,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578627"
    },
    {
      "nct_id": "NCT03159702",
      "title": "Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancy",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Evomela",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Haploidentical Hematopoietic Cell Transplantation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2017-12-08",
      "completion_date": "2025-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03159702"
    },
    {
      "nct_id": "NCT01577550",
      "title": "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "BI 655066 (very high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, i.v.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high medium i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (very low i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low s.c. dose)",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (high i.v. dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, s.c.",
          "type": "DRUG"
        },
        {
          "name": "BI 655066 (low medium i.v. dose)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 39,
      "start_date": "2012-04",
      "completion_date": "2014-05",
      "has_results": false,
      "last_update_posted_date": "2016-11-16",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 7,
      "location_summary": "Burbank, California • Miami, Florida • Port Orange, Florida + 4 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577550"
    },
    {
      "nct_id": "NCT01079923",
      "title": "Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Single High Dose Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Daily Dose Cholecalciferol",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2010-02",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2012-11-20",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01079923"
    },
    {
      "nct_id": "NCT04890873",
      "title": "ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "ERX1000",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ERX Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2019-10-17",
      "completion_date": "2023-07-03",
      "has_results": false,
      "last_update_posted_date": "2023-10-24",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04890873"
    },
    {
      "nct_id": "NCT00376896",
      "title": "Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Irritable Colon",
        "Irritable Bowel Syndrome (IBS)"
      ],
      "interventions": [
        {
          "name": "GW876008 200mcg",
          "type": "DRUG"
        },
        {
          "name": "GW876008 20mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 25,
      "start_date": "2006-11",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-11-03T12:22:00.582Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00376896"
    }
  ]
}